Signal in previously treated biliary tract cancer at #ESMO26:
Tovecimig + paclitaxel improves ORR (17% vs 5%) and PFS (HR 0.44)…but with substantial toxicity, and OS remains uninterpretable given 54% crossover 🤷🏻♂️
@OncoAlert 4Sight is already dissecting the abstracts worth watching! 👀
@OncoReporte @_SEOM @myESMO
54 views · 4 likes · 4 reposts · 0 replies
FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab as second-line therapy for taxane-pretreated patients with advanced or metastatic gastroesophageal adenocarcinoma–Final results of the phase III IKFs602/AIO RAMIRIS Study
https://esmocongress.esmo.orgDESTINY-Breast11: MRI-assessed objective responses during neoadjuvant treatment (NAT) with trastuzumab deruxtecan (T-DXd) followed by paclitaxel + trastuzumab + pertuzumab (THP) vs dose-dense doxorubicin + cyclophosphamide followed by THP (
https://esmocongress.esmo.orgDurvalumab (D) plus carboplatin/paclitaxel (CP) followed by D with or without olaparib (O) in advanced/recurrent endometrial cancer (a/rEC): Interim overall survival (OS) and safety from the randomised phase 3 DUO-E/GOG-3041/ENGOT-EN10 stud
https://esmocongress.esmo.orgOncoAlert 4Sight Abstracts to be Presented at #ESMO26 A Randomized Trial of Paclitaxel ± Tovecimig in Previously Treated Patients With Advanced Biliary Tract Cancer @DrElkhoueiry @JavleMilind 🔬 Randomized phase 2/3 (n=168, 2:1): tovecimig (DLL4 × VEGF-A bispecific) + paclitaxel vs paclitaxel in previously treated advanced BTC. Primary endpoint: BICR ORR. ➡️ ORR 17.1% vs 5.3% (p=0.031); median PFS 4.7 vs 2.6 mo, HR 0.44 (p<0.0001) ➡️ OS HR 1.05 (p=0.78); 54% crossed over to tovecimig + paclitaxel ➡️ Related grade ≥3 hypertension 44%; TEAEs leading to discontinuation 40% vs 15% ✅ Significant ORR and PFS advantage; OS analysis confounded by high crossover, precluding a meaningful comparison. 🎙️ Nilofer Azad 👥 Zishuo Hu · Ilyas Sahin · Renuka Iyer · Olivia Aranha · Howard Hochster · Priyadarshini Pathak · Scott Paulson · Aparna Kalyan · Chih-Yi Liao · Nguyen Tran · Robin Kelley · Gregory Heestand · David Cosgrove · Anthony El-Khoueiry · Mitesh Borad · Nashat Gabrail · Umair Majeed · Lingling Du · Suneel Kamath · Nathan Shumway · Rachna Shroff · Lipika Goyal · Minori Rosales · Milind Javle (4Sight Made from Abstracts publicly available at the ESMO website) @CathyEngMD, @BenWestphalen, @graokane, @NiuSanford, , @GillSharlene, @pashtoonkasi, @DrVilmaPBarcia, @Erman_Akkus, @GIMedOnc, @UOzkerim, @MarioBalsaMD, @p_ciracimd, @DraMartinezLago, @DaisukeKotani, @Aiims1742, @ARosen380, @realbowtiedoc, @KoheiShitara,在 X 查看被引用的帖子
Source: Mario Balsa · x.com